ClinicalTrials.gg

Program

basmisanil

Also written as “RG1662”, “Basmisanil” and “RO5186582”.

Its studies are mostly in Down Syndrome · Schizophrenia · Stroke, led by 2 companies.

Furthest: phase 2, since Dec 27, 201313 company-led studies, 1 open or runningNext primary completion: May 1, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche120 open or runningphase 2since Dec 27, 2013Aug 18, 2011none ahead
Newleos Therapeutics11 open or runningphase 2since Sep 18, 2026Sep 18, 2026May 1, 2029phase 2 · NCT07846215

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 18, 2011First study: phase 1 study in Down SyndromeNew to Hoffmann-La RocheHoffmann-La Roche · NCT01436955 · 35 enrolled · United States, United Kingdom
  2. Aug 14, 2012Phase 1 study in Down SyndromeHoffmann-La Roche · NCT01667367 · 13 enrolled · United Kingdom
  3. Sep 11, 2012Phase 1 study in Healthy VolunteerHoffmann-La Roche · NCT01684891 · 6 enrolled · Netherlands
  4. Dec 27, 2013Phase 2 study in Down SyndromeHoffmann-La Roche · NCT02024789 · 173 enrolled · United States, Argentina, Canada and more
  5. Jul 8, 2014Phase 1 study in Healthy VolunteerHoffmann-La Roche · NCT02194244 · 18 enrolled · United Kingdom
  6. Sep 23, 2014Phase 1 study in Healthy VolunteerHoffmann-La Roche · NCT02254759 · 12 enrolled · United Kingdom
  7. May 13, 2015Phase 1 study in Healthy Patient StudyHoffmann-La Roche · NCT02470832 · 12 enrolled · United Kingdom
  8. Jun 16, 2015Phase 2 study in Down SyndromeHoffmann-La Roche · NCT02484703 · 45 enrolled · United States
  9. Aug 21, 2015Phase 1 study in Healthy VolunteerHoffmann-La Roche · NCT02534207 · 6 enrolled · United Kingdom
  10. Oct 7, 2016Phase 2 study in StrokeHoffmann-La Roche · NCT02928393 · 5 enrolled · France, Spain
  11. Nov 1, 2016Phase 2 study in SchizophreniaHoffmann-La Roche · NCT02953639 · 214 enrolled · United States
  12. Mar 25, 2022Phase 2 study in Polyposis Syndrome, Hereditary Mixed, 1Hoffmann-La Roche · NCT05307679 · 7 enrolled · United States, Spain, United Kingdom
  13. Sep 18, 2026Newleos Therapeutics's first study: phase 2 study in Dup15Q SyndromeNew to Newleos TherapeuticsNewleos Therapeutics · NCT07846215 · 30 planned · United States

Ahead

  1. May 1, 2029Primary completion: phase 2 study in Dup15Q SyndromeNewleos Therapeutics · NCT07846215

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07846215Dup15Q Syndrome · United States2Not yet recruitingNewleos TherapeuticsMay 1, 202930
NCT05307679Polyposis Syndrome, Hereditary Mixed, 1 · United States, Spain, United Kingdom2TerminatedHoffmann-La RocheMar 4, 20247
NCT02953639Schizophrenia · United States2CompletedHoffmann-La RocheDec 12, 2019214
NCT02928393Stroke · France, Spain2TerminatedHoffmann-La RocheNov 3, 20175
NCT02534207Healthy Volunteer · United Kingdom1CompletedHoffmann-La RocheOct 20156
NCT02484703Down Syndrome · United States2TerminatedHoffmann-La RocheAug 3, 201645
NCT02470832Healthy Patient Study · United Kingdom1CompletedHoffmann-La RocheJul 201512
NCT02254759Healthy Volunteer · United Kingdom1CompletedHoffmann-La RocheNov 201412
NCT02194244Healthy Volunteer · United Kingdom1CompletedHoffmann-La RocheAug 201418
NCT02024789Down Syndrome · United States, Argentina, Canada and more2CompletedHoffmann-La RocheMay 4, 2016173
NCT01684891Healthy Volunteer · Netherlands1CompletedHoffmann-La RocheOct 20126
NCT01667367Down Syndrome · United Kingdom1CompletedHoffmann-La RocheOct 201313
NCT01436955Down Syndrome · United States, United Kingdom1CompletedHoffmann-La RocheSep 201335

How it is read

Names in the registry

  • “RG1662”, 6 entries
  • “Basmisanil”, 5 entries
  • “RO5186582”, 2 entries
  • “RG1662 granules”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.